Klin Onkol 2004; 17(Suppl 1): 51-56.
Abstract: Cytogenetics and molecular genetics become an essential part of diagnostics and prognostification in oncology of both the solid tumors and hematological malignancies. Their significance has been confirmed in large multicentric prospective or retrospective studies and they were successfully incorporated in routine clinical diagnostics and patient stratification. Cytogenetic and/or genetic alterations were detected in 60-90% of leukemias and solid tumors, and those involve specific changes applicable for identification of high-risk individuals, disease prognostification, prediction of therapy response or monitoring of disease activity. In this paper we underline importance of those markers in diagnostics, prognostification and prediction of therapy response in patients suffering from breast cancer, chronic myeloid leukemia and acute promyelocytic leukemia within the frames of medical and economical consequences.
